IL271346A - Bispecific antibodies and methods of making and using thereof - Google Patents

Bispecific antibodies and methods of making and using thereof

Info

Publication number
IL271346A
IL271346A IL271346A IL27134619A IL271346A IL 271346 A IL271346 A IL 271346A IL 271346 A IL271346 A IL 271346A IL 27134619 A IL27134619 A IL 27134619A IL 271346 A IL271346 A IL 271346A
Authority
IL
Israel
Prior art keywords
preparation
methods
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
IL271346A
Other languages
English (en)
Hebrew (he)
Original Assignee
Systimmune Inc
Sichuan Baili Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc, Sichuan Baili Pharmaceutical Co Ltd filed Critical Systimmune Inc
Publication of IL271346A publication Critical patent/IL271346A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL271346A 2017-11-02 2019-12-11 Bispecific antibodies and methods of making and using thereof IL271346A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580845P 2017-11-02 2017-11-02
PCT/US2018/058810 WO2019090002A1 (en) 2017-11-02 2018-11-01 Bispecific antibodies and methods of making and using thereof

Publications (1)

Publication Number Publication Date
IL271346A true IL271346A (en) 2020-01-30

Family

ID=66332369

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271346A IL271346A (en) 2017-11-02 2019-12-11 Bispecific antibodies and methods of making and using thereof

Country Status (11)

Country Link
US (1) US20200347137A1 (enExample)
EP (1) EP3703736A4 (enExample)
JP (1) JP7418326B2 (enExample)
KR (2) KR102785809B1 (enExample)
CN (2) CN117343193A (enExample)
AU (1) AU2018358138C1 (enExample)
CA (1) CA3069238A1 (enExample)
IL (1) IL271346A (enExample)
SG (1) SG11202003237QA (enExample)
TW (1) TWI896517B (enExample)
WO (1) WO2019090002A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7383605B2 (ja) * 2017-06-25 2023-11-20 システィミューン， インク． 抗ｐｄ－ｌ１抗体とその作製及び使用方法
US12649792B2 (en) 2019-05-06 2026-06-09 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
EP4061849A4 (en) * 2019-11-21 2024-05-29 Brown University BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND CTLA4 WITH IMPROVED CYTOTOXIC EFFECTS ON TUMOR CELLS
EP4069746A4 (en) * 2019-12-04 2023-12-27 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. BISPECIFIC FUSION PROTEIN FOR TUMOR TREATMENT
TW202511295A (zh) * 2023-08-31 2025-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途
CN122161858A (zh) * 2023-09-18 2026-06-05 翰思艾泰生物医药科技(武汉)股份有限公司 靶向ctla4和cd47的抗体及其用途
WO2026061422A1 (en) * 2024-09-18 2026-03-26 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Methods for treating cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496134T1 (de) * 2002-03-29 2011-02-15 Xoma Technology Ltd Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden
US8399618B2 (en) * 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
AU2006230413B8 (en) * 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
EP3683314A1 (en) * 2013-10-07 2020-07-22 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
CN104974253A (zh) 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
US10196445B1 (en) * 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
CN104987421A (zh) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
AU2018366199A1 (en) * 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences

Also Published As

Publication number Publication date
TWI896517B (zh) 2025-09-11
SG11202003237QA (en) 2020-05-28
TW201927819A (zh) 2019-07-16
US20200347137A1 (en) 2020-11-05
JP2021501575A (ja) 2021-01-21
RU2020108444A3 (enExample) 2022-03-17
CN111212658B (zh) 2024-05-03
AU2018358138A1 (en) 2020-04-23
EP3703736A4 (en) 2021-11-03
CA3069238A1 (en) 2019-05-09
NZ763370A (en) 2024-10-25
CN111212658A (zh) 2020-05-29
CN117343193A (zh) 2024-01-05
KR20250044943A (ko) 2025-04-01
KR20200091382A (ko) 2020-07-30
EP3703736A1 (en) 2020-09-09
KR102785809B1 (ko) 2025-03-26
AU2018358138B2 (en) 2022-06-02
JP7418326B2 (ja) 2024-01-19
AU2018358138C1 (en) 2022-12-08
WO2019090002A1 (en) 2019-05-09
RU2020108444A (ru) 2021-12-02

Similar Documents

Publication Publication Date Title
IL272274A (en) B7-h4 antibodies and methods of use thereof
IL286835A (en) Bispecific tetravalent antibodies and methods of makiing and using thereof
IL271179A (en) Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies
IL271260A (en) Multi-specific antibodies and methods of making and using thereof
IL262095A (en) Anti-pacap antibodies and uses thereof
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
IL271257A (en) Multi-specific antibodies and methods of making and using thereof
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
IL257772A (en) Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use
IL253166A0 (en) Bispecific antibodies against cd3 and cd20
IL254039A0 (en) Anti-pvrig antibodies and methods of use
DK3353212T3 (da) Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
HRP20260300T1 (hr) Kimerni antigenski receptori temeljeni na jednodomenskim antitijelima i njihove metode uporabe
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
CL2016002462A1 (es) Anticuerpos anti-ox40 y métodos de uso
HUE054384T2 (hu) EGFRVIII-T és CD3-at kötõ bispecifikus antitest-konstrukciók
HUE048284T2 (hu) Anti-CD40 antitestek és alkalmazásuk
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
HUE048111T2 (hu) Anti-CEACAM6 ellenanyagok és alkalmazásuk
HUE050750T2 (hu) CTLA-4 elleni antitestek és eljárások alkalmazásukra
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
PT3148579T (pt) Anticorpos anti-gitr e métodos da sua utilização
DK3310812T3 (da) Anti-HER2-antistoffer og fremgangsmåder til anvendelse
IL263627A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use